Navigation Links
Scripps Research scientists show potent new compound virtually eliminates HIV in cell culture
Date:7/19/2012

JUPITER, FL, July 19, 2012 A new study by scientists on the Florida campus of The Scripps Research Institute shows, in cell culture, a natural compound can virtually eliminate human immunodeficiency virus (HIV) in infected cells. The compound defines a novel class of HIV anti-viral drugs endowed with the capacity to repress viral replication in acutely and chronically infected cells.

The HIV/AIDS pandemic continues to affect 34 million individuals worldwide, including more than 3 million children, according to the World Health Organization. Current treatment involves the use of several antiretroviral drugs, termed Highly Active Antiretroviral Therapy (HAART), which can extend the life expectancy of HIV-positive individuals and decrease viral load without, however, eradicating the virus.

"We know that there are reservoirs of HIV that aren't being eliminated by current treatment and that keep replenishing the infection," said Susana Valente, a Scripps Research biologist who led the study. "Viral production from these cellular reservoirs that harbor an integrated viral genome is not affected by current antiretroviral drugs, which only stop novel rounds of infection. The compound in the current study virtually eliminates all viral replication from already-infected cells where HIV hides."

The new study, published in the July 20, 2012 issue of the journal Cell Host and Microbe, focused on a medically promising compound known as Cortistatin A. This natural product was isolated in 2006 from a marine sponge, Corticium simplex, discovered more than 100 years ago. In 2008, Scripps Research chemist Phil Baran and his team won the global race to synthesize the compound, presenting an efficient and economical method.

In the new study, Valente and her colleagues collaborated with the Baran lab, using a synthetic version of the compound, didehydro-Cortistatin A, to study the compound's effect on two strains of HIV. The strains were HIV-1, the most common form of the virus, and HIV-2, which is concentrated in West Africa and some parts of Europe.

The results showed that the compound reduced viral production by 99.7 percent from primary CD4+T cells (a type of immune cell) isolated from patients without levels of the virus in their bloodstream and who had been under HAART treatment for a long period of time. When the compound was added to other antiviral treatments, it further reduced by 20 percent viral replication from CD4+T cells isolated from patients with detectable amounts of virus in their bloodstreams.

The inhibitor works by binding tightly to the viral protein known as Tat, a potent activator of HIV gene expression, effectively preventing the virus from replicating even at miniscule concentrationsmaking it the most potent anti-Tat inhibitor described to date, Valente said. Another interesting feature of this compound is that withdrawal of the drug from cell culture does not result in virus rebound, which is normally observed with other antiretrovirals.

While most antiretroviral compounds block only new infections, didehydro-Cortistatin A reduces viral replication from already-infected cells, potentially limiting cell-to-cell transmission.

The new inhibitor already has a drug-like structure, is effective at very low concentrations, and has no toxicity associated with it, at least at the cellular level, the study noted.


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps Research Institute wins $77 million to develop AIDS vaccine center
2. Scripps Florida scientists identify critical quality control for cell growth
3. Scripps Research Institute Scientists Develop Alternative to Gene Therapy
4. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
5. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
6. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
7. Plastic trash altering ocean habitats, Scripps study shows
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
10. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
11. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research scientists show potent new compound virtually eliminates HIV in cell culture
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial ... trial sites and study participants truly unified. TrialKit, a native mobile app, empowers ... Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers can ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... States Patent and Trademark Office for its Patent Applications 14/858,857 and 13/669,785 both ... of these patent applications further expand the protection of G-CON’s R&D investments and ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... device testing capabilities to encompass the full series of ISO 80369 standard test ... fittings for medical device and drug delivery systems. With this recent expansion, Whitehouse ...
(Date:7/17/2017)... Linda, Ca (PRWEB) , ... July 17, 2017 ... ... heterogeneous and are characterized by a wide range of overlapping clinical features. The ... of discovery in the field of NDD research and testing. , However, ...
Breaking Biology Technology: